Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.

Item

http://www.wikidata.org/entity/Q40187323

Q40187323

about

Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-lactamase Inhibitor, Dosed in Combination with Imipenem/Cilastatin in Healthy Subjects.New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms.How to manage Pseudomonas aeruginosa infections.β-lactam/β-lactamase inhibitor combinations: an update Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant

P2860

Q46243175-293F4FC1-C307-4C9C-BB0D-9643EA8FA5A7 Q47195583-A124A79D-95B4-4C5A-8FC2-106D57945635 Q49540457-53AEB9CC-A482-42D7-8437-3DE603BD0660 Q54977074-2EFB00D5-09CC-432B-8196-2EE300BB63A4 Q57133147-308D41F0-A426-49B8-B6CD-1D7106954B16 Q58700555-E8F3C917-58B2-495B-B7D6-9A0A964A6DF8 Q58746821-7EA7EC3F-0876-49B7-8A40-E1E31471A168

P2860

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.

Item

http://www.wikidata.org/entity/Q40187323

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Prospective, randomized, doubl ...... ated urinary tract infections.

@en

type

Item

label

Prospective, randomized, doubl ...... ated urinary tract infections.

@en

prefLabel

Prospective, randomized, doubl ...... ated urinary tract infections.

@en

P1476

Prospective, randomized, doubl ...... ated urinary tract infections.

@en

P2093

Alison Pedley

http://www.w3.org/2001/XMLSchema#string

Amanda Paschke

http://www.w3.org/2001/XMLSchema#string

Jiejun Du

http://www.w3.org/2001/XMLSchema#string

Matthew Sims

http://www.w3.org/2001/XMLSchema#string

Michelle L Brown

http://www.w3.org/2001/XMLSchema#string

Nicholas A Kartsonis

http://www.w3.org/2001/XMLSchema#string

Patrick McLeroth

http://www.w3.org/2001/XMLSchema#string

Valeri Mariyanovski

http://www.w3.org/2001/XMLSchema#string

Wayne Akers

http://www.w3.org/2001/XMLSchema#string

Yu-Chieh Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis

Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®

Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America

International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults.

Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates

Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.

Newer carbapenems for urinary tract infections.

P304

2616-2626

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKX139

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28575389

http://www.w3.org/2001/XMLSchema#string

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.

about

P2860

P2860

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698